Drug Search Results
More Filters [+]

TAR-210

Alternative Names: TAR-210, TAR 210, TAR210
Latest Update: 2024-07-17
Latest Update Note: News Article

Product Description

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TAR-210

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United States, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Bladder Cancer|Muscle Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MoonRISe-1

P3

Recruiting

Bladder Cancer|Muscle Cancer

2028-06-28

jRCT2031240100

P3

Not yet recruiting

Muscle Cancer|Bladder Cancer

2028-06-10

Recent News Events